Recently, beta emitter labeled analogs of CXCR4-ligands ([177Lu]/[90Y] Pentixather) have been tested as a novel therapeutic approach in patients with hematological neoplasm (i.e. multiple myeloma). The gene discussed is CXCR4; the disease is plasma cell myeloma.